Profil
Nathan Chen worked as the Director of Regional Clinical Development at Boehringer Ingelheim Corp.
He then served as the Head of Immunology & Inflammation at GSK Plc from 2018 to 2020.
Currently, he is the Vice President of Regulatory Affairs at LianBio.
Mr. Chen holds graduate degrees from Purdue University, Rensselaer Polytechnic Institute, and the State University of New York at Albany.
Anciens postes connus de Nathan Chen
| Sociétés | Poste | Fin |
|---|---|---|
| LIANBIO | Conseiller Juridique Général | 01/02/2023 |
| GSK PLC | Corporate Officer/Principal | 01/02/2020 |
Boehringer Ingelheim Corp.
Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets health care products | Corporate Officer/Principal | - |
Formation de Nathan Chen
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
GSK Plc
GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
Purdue University
Purdue University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rensselaer Polytechnic Institute
Rensselaer Polytechnic Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
State University of New York at Albany
State University of New York at Albany Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Boehringer Ingelheim Corp.
Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets health care products | Health Technology |
LianBio
LianBio BiotechnologyHealth Technology Operates as a biotechnology company focused on bringing paradigm-shifting medicines to patients | Health Technology |
















